Grid Therapeutics
Grid Therapeutics, a biotech firm, pioneers in developing human-derived targeted immunotherapy for cancer.
Founded
2014Grid Therapeutics, a biotech firm, pioneers in developing human-derived targeted immunotherapy for cancer.
Grid Therapeutics, founded by Edward F. Patz, Jr. MD and his team at Duke University Medical Center, is a clinical-stage biotechnology company based in Durham, North Carolina. The company's core mission is to develop innovative, human-derived targeted immunotherapies for cancer. Their lead product, "GT103," is an antibody discovered in early-stage lung cancer patients, isolated using advanced molecular genomic techniques. Grid Therapeutics focuses on harnessing the power of the human immune system to create safer and more effective cancer treatments.
Notable figures affiliated with Grid Therapeutics include its founder, Edward F. Patz, Jr., who is a prominent scientist at Duke University Medical Center. The company has attracted significant attention and investment due to its groundbreaking approach to cancer therapy. Key achievements include the development and clinical progression of GT103, which represents a novel class of tumor-specific therapeutic antibodies. Grid Therapeutics' impact lies in its potential to revolutionize cancer treatment by offering targeted, patient-derived immunotherapies that promise improved outcomes and reduced side effects for cancer patients.
Companies similar to Grid Therapeutics include G1 Therapeutics, GO Therapeutics, Grit Bio and Gritstone bio.
Grid Therapeutics was founded in 2014.
Grid Therapeutics' headquarters is located in Durham, NC, US.
Grid Therapeutics' most recent funding round was for $5M (USD) in March 2018.
As of Mar 27, 2018, Grid Therapeutics has raised a total of $5M (USD).
Grid Therapeutics has 10 employees as of Feb 5, 2024.
Grit Bio
